Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes

  • Reynders, Tatjana
  • Devolder, Lindsay
  • Vallès Colomer, Mireia
  • Van Remoortel, Ann
  • Joossens, Marie
  • De Keyser, Jacques
  • Nagels, Guy
  • D'hooghe, Marie Beatrice
  • Raes, Jeroen
Objective: Multiple sclerosis (MS) is a heterogenous, inflammatory disease of the central nervous system. Microbiota alterations in MS versus healthy controls (HC) are observed, but results are inconsistent. We studied diversity, enterotypes, and specific gut microbial taxa variation between MS and HC, and between MS subgroups. Methods: Amplicon sequencing of the 16S ribosomal RNA V4 region (Illumina MiSeq) was used to evaluate alpha and beta diversity, enterotypes, and relative taxa abundances on stool samples. MS subgroups were based on phenotype, disease course modifiers, and treatment status. Results were controlled for recently identified confounders of microbiota composition. Results: Ninety-eight MS patients and 120 HC were included. Microbial richness was lower in interferon-treated (RRMS_I, N = 24) and untreated relapsing-remitting MS during relapse (RRMS_R, N = 4) when compared to benign (BMS, N = 20; Z = -3.07, Pcorr = 0.032 and Z = -2.68, Pcorr = 0.055) and primary progressive MS (PPMS, N = 26; Z = -2.39, Pcorr = 0.062 and Z = -2.26, Pcorr = 0.071). HC (N = 120) and active untreated MS (RRMS_U, N = 24) showed intermediate microbial richness. Enterotypes were associated with clinical subgroups (N = 218, χ2 = 36.10, P = 0.002), with Bacteroides 2 enterotype being more prevalent in RRMS_I. Butyricicoccus abundance was lower in PPMS than in RRMS_U (Z = -3.00, Pcorr = 0.014) and BMS (Z = -2.56, Pcorr = 0.031), lower in RRMS_I than in BMS (Z = -2.50, Pcorr = 0.034) and RRMS_U (Z = -2.91, Pcorr = 0.013), and inversely correlated with self-reported physical symptoms (rho = -0.400, Pcorr = 0.001) and disease severity (rho = -0.223, P = 0.027). Interpretation: These results emphasize the importance of phenotypic subcategorization in MS-microbiome research, possibly explaining previous result heterogeneity, while showing the potential for specific microbiome-based biomarkers for disease activity and severity., MJ is funded by a postdoctoral fellowship from Research Foundation—Flanders. The Raes lab is supported by the VIB, the Rega institute for Medical Research, KU Leuven, the FWO EOS program (30770923), FP7 METACARDIS (305312), H2020 SYSCID (733100), PIBD-SET (668023), and IMMUNAID (779295). This work was funded by an FWO research grant (G038318N) to MD and JR. Financial support for this project in the MS center was provided in 2015, 2016 and 2017, commissioned by the Belgian National MS society with the support of the Fund D.V., managed by the King Baudouin Foundation (2016-C5812060-206012).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection

  • Andreakos, Evangelos
  • Abel, Laurent
  • Vinh, Donald C.
  • Kaja, Elżbieta
  • Drolet, Beth A.
  • Zhang, Qian
  • O’Farrelly, Cliona
  • Novelli, Giuseppe
  • Rodríguez-Gallego, Carlos
  • Haerynck, Filomeen
  • Prando, Carolina
  • Pujol, Aurora
  • COVID Human Genetic Effort
  • Su, Helen C.
  • Casanova, Jean-Laurent
  • Spaan, András N.
SARS-CoV-2 infections display tremendous interindividual variability, ranging from asymptomatic infections to life-threatening disease. Inborn errors of, and autoantibodies directed against, type I interferons (IFNs) account for about 20% of critical COVID-19 cases among SARS-CoV-2-infected individuals. By contrast, the genetic and immunological determinants of resistance to infection per se remain unknown. Following the discovery that autosomal recessive deficiency in the DARC chemokine receptor confers resistance to Plasmodium vivax, autosomal recessive deficiencies of chemokine receptor 5 (CCR5) and the enzyme FUT2 were shown to underlie resistance to HIV-1 and noroviruses, respectively. Along the same lines, we propose a strategy for identifying, recruiting, and genetically analyzing individuals who are naturally resistant to SARS-CoV-2 infection., The Laboratory of Human Genetics of Infectious Diseases is supported by the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the Investments for the Future program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS-COV05, the Fondation du Souffle, the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM), and the University of Paris. E.A. is supported by research grants from the European Commission’s Horizon 2020 research and innovation program (IMMUNAID, grant no. 779295, CURE, grant no. 767015 and TO_AITION grant no. 848146) and the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). C.O.F. is supported in part by the Science Foundation Ireland COVID-19 Program. G.N. is supported by a grant awarded to Regione Lazio (Research Group Projects 2020) no. A0375-2020-36663, GecoBiomark. A.P. is supported in part by the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342) and the CERCA Program/Generalitat de Catalunya. H.S. is supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. A.S. is supported in part by the European Union’s Horizon 2020 research and innovation program (Marie Sklodowska-Curie grant no. 789645).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis

  • Régnier, Paul
  • Le Joncour, Alexandre
  • Maciejewski-Duval, Anna
  • Darrasse-Jèze, Guillaume
  • Dolladille, Charles
  • Meijers, Wouter C.
  • Bastarache, Lisa
  • Fouret, Pierre
  • Bruneval, Patrick
  • Arbaretaz, Florianne
  • Sayetta, Célia
  • Márquez, Ana
  • Rosenzwajg, Michelle
  • Klatzmann, David
  • Cacoub, Patrice
  • Moslehi, Javid J.
  • Salem, Joe-Elle
  • Saadoun, David
BACKGROUND: Giant cell arteritis (GCA) causes severe inflammation of the aorta and its branches and is characterized by intense effector T-cell infiltration. The roles that immune checkpoints play in the pathogenesis of GCA are still unclear. Our aim was to study the immune checkpoint interplay in GCA. METHODS: First, we used VigiBase, the World Health Organization international pharmacovigilance database, to evaluate the relationship between GCA occurrence and immune checkpoint inhibitors treatments. We then further dissected the role of immune checkpoint inhibitors in the pathogenesis of GCA, using immunohistochemistry, immunofluorescence, transcriptomics, and flow cytometry on peripheral blood mononuclear cells and aortic tissues of GCA patients and appropriated controls. RESULTS: Using VigiBase, we identified GCA as a significant immune-related adverse event associated with anti-CTLA-4 (cytotoxic T-lymphocyte¿associated protein-4) but not anti-PD-1 (anti-programmed death-1) nor anti-PD-L1 (anti-programmed death-ligand 1) treatment. We further dissected a critical role for the CTLA-4 pathway in GCA by identification of the dysregulation of CTLA-4¿derived gene pathways and proteins in CD4+ (cluster of differentiation 4) T cells (and specifically regulatory T cells) present in blood and aorta of GCA patients versus controls. While regulatory T cells were less abundant and activated/suppressive in blood and aorta of GCA versus controls, they still specifically upregulated CTLA-4. Activated and proliferating CTLA-4+ Ki-67+ regulatory T cells from GCA were more sensitive to anti-CTLA-4 (ipilimumab)¿mediated in vitro depletion versus controls. CONCLUSIONS: We highlighted the instrumental role of CTLA-4 immune checkpoint in GCA, which provides a strong rationale for targeting this pathway., This project has received funding from the European Union Horizon 2020 research and innovation program under grant agreement number 779295., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes

  • Reynders, Tatjana
  • Devolder, Lindsay
  • Vallès Colomer, Mireia
  • Van Remoortel, Ann
  • Joossens, Marie
  • De Keyser, Jacques
  • Nagels, Guy
  • D'hooghe, Marie Beatrice
  • Raes, Jeroen
Objective: Multiple sclerosis (MS) is a heterogenous, inflammatory disease of the central nervous system. Microbiota alterations in MS versus healthy controls (HC) are observed, but results are inconsistent. We studied diversity, enterotypes, and specific gut microbial taxa variation between MS and HC, and between MS subgroups. Methods: Amplicon sequencing of the 16S ribosomal RNA V4 region (Illumina MiSeq) was used to evaluate alpha and beta diversity, enterotypes, and relative taxa abundances on stool samples. MS subgroups were based on phenotype, disease course modifiers, and treatment status. Results were controlled for recently identified confounders of microbiota composition. Results: Ninety-eight MS patients and 120 HC were included. Microbial richness was lower in interferon-treated (RRMS_I, N = 24) and untreated relapsing-remitting MS during relapse (RRMS_R, N = 4) when compared to benign (BMS, N = 20; Z = -3.07, Pcorr = 0.032 and Z = -2.68, Pcorr = 0.055) and primary progressive MS (PPMS, N = 26; Z = -2.39, Pcorr = 0.062 and Z = -2.26, Pcorr = 0.071). HC (N = 120) and active untreated MS (RRMS_U, N = 24) showed intermediate microbial richness. Enterotypes were associated with clinical subgroups (N = 218, χ2 = 36.10, P = 0.002), with Bacteroides 2 enterotype being more prevalent in RRMS_I. Butyricicoccus abundance was lower in PPMS than in RRMS_U (Z = -3.00, Pcorr = 0.014) and BMS (Z = -2.56, Pcorr = 0.031), lower in RRMS_I than in BMS (Z = -2.50, Pcorr = 0.034) and RRMS_U (Z = -2.91, Pcorr = 0.013), and inversely correlated with self-reported physical symptoms (rho = -0.400, Pcorr = 0.001) and disease severity (rho = -0.223, P = 0.027). Interpretation: These results emphasize the importance of phenotypic subcategorization in MS-microbiome research, possibly explaining previous result heterogeneity, while showing the potential for specific microbiome-based biomarkers for disease activity and severity., MJ is funded by a postdoctoral fellowship from Research Foundation—Flanders. The Raes lab is supported by the VIB, the Rega institute for Medical Research, KU Leuven, the FWO EOS program (30770923), FP7 METACARDIS (305312), H2020 SYSCID (733100), PIBD-SET (668023), and IMMUNAID (779295). This work was funded by an FWO research grant (G038318N) to MD and JR. Financial support for this project in the MS center was provided in 2015, 2016 and 2017, commissioned by the Belgian National MS society with the support of the Fund D.V., managed by the King Baudouin Foundation (2016-C5812060-206012).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning

  • Mueller, Yvonne
  • Schrama, Thijs
  • Ruijten, Rik
  • Schreurs, Marco WJ
  • Grashof, Dwin
  • van de Werken, Harmen J. G.
  • Álvarez de la Sierra, Daniel
  • Hernández González, Manuel
  • Pujol Borrell, Ricardo
Applied immunology; Predictive markers; Viral infection, Immunologia aplicada; Marcadors predictius; Infecció viral, Inmunología aplicada; Marcadores predictivos; Infección viral, Quantitative or qualitative differences in immunity may drive clinical severity in COVID-19. Although longitudinal studies to record the course of immunological changes are ample, they do not necessarily predict clinical progression at the time of hospital admission. Here we show, by a machine learning approach using serum pro-inflammatory, anti-inflammatory and anti-viral cytokine and anti-SARS-CoV-2 antibody measurements as input data, that COVID-19 patients cluster into three distinct immune phenotype groups. These immune-types, determined by unsupervised hierarchical clustering that is agnostic to severity, predict clinical course. The identified immune-types do not associate with disease duration at hospital admittance, but rather reflect variations in the nature and kinetics of individual patient’s immune response. Thus, our work provides an immune-type based scheme to stratify COVID-19 patients at hospital admittance into high and low risk clinical categories with distinct cytokine and antibody profiles that may guide personalized therapy., This work was supported by Health Holland LSHM20056 grant (PDK), in part from the European Union’s Horizon 2020 research and innovation program under grant agreement No 779295 (PDK), in part supported by the Erasmus foundation (BJAR), grant PI20/00416 from the Instituto de Salud Carlos III (RPB) and the European Regional Development Fund (ERDF) (RPB).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning

  • Mueller, Yvonne M.|||0000-0002-4654-7509
  • Schrama, Thijs J.|||0000-0002-6693-4725
  • Ruijten, Rik
  • Schreurs, Marco W. J.
  • Grashof, Dwin G. B.|||0000-0002-4169-9888
  • van de Werken, Harmen J. G.|||0000-0002-9794-1477
  • Lasinio, Giovanna Jona|||0000-0001-8912-5018
  • Álvarez-Sierra, Daniel|||0000-0001-8221-5117
  • Kiernan, Caoimhe H.
  • Castro Eiro, Melisa D.|||0000-0003-0780-8937
  • van Meurs, Marjan
  • Brouwers-Haspels, Inge|||0000-0003-4492-446X
  • Zhao, Manzhi
  • Li, Ling
  • de Wit, Harm
  • Ouzounis, Christos|||0000-0002-0086-8657
  • Wilmsen, Merel E. P.
  • Alofs, Tessa M.
  • Laport, Danique A.
  • van Wees, Tamara
  • Kraker, Geoffrey
  • Jaimes, Maria C.
  • Van Bockstael, Sebastiaan
  • Hernández-González, Manuel|||0000-0002-6932-5853
  • Rokx, Casper|||0000-0002-1904-6450
  • Rijnders, Bart J. A.|||0000-0003-3343-9610
  • Pujol-Borrell, Ricardo|||0000-0001-7833-675X
  • Katsikis, Peter D.|||0000-0001-7690-5218
Quantitative or qualitative differences in immunity may drive clinical severity in COVID-19. Although longitudinal studies to record the course of immunological changes are ample, they do not necessarily predict clinical progression at the time of hospital admission. Here we show, by a machine learning approach using serum pro-inflammatory, anti-inflammatory and anti-viral cytokine and anti-SARS-CoV-2 antibody measurements as input data, that COVID-19 patients cluster into three distinct immune phenotype groups. These immune-types, determined by unsupervised hierarchical clustering that is agnostic to severity, predict clinical course. The identified immune-types do not associate with disease duration at hospital admittance, but rather reflect variations in the nature and kinetics of individual patient's immune response. Thus, our work provides an immune-type based scheme to stratify COVID-19 patients at hospital admittance into high and low risk clinical categories with distinct cytokine and antibody profiles that may guide personalized therapy. Developing predictive methods to identify patients with high risk of severe COVID-19 disease is of crucial importance. Authors show here that by measuring anti-SARS-CoV-2 antibody and cytokine levels at the time of hospital admission and integrating the data by unsupervised hierarchical clustering/machine learning, it is possible to predict unfavourable outcome.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning

  • Mueller, Yvonne
  • Schrama, Thijs
  • Ruijten, Rik
  • Schreurs, Marco WJ
  • Grashof, Dwin
  • van de Werken, Harmen J. G.
  • Álvarez de la Sierra, Daniel
  • Hernández González, Manuel
  • Pujol Borrell, Ricardo
Applied immunology; Predictive markers; Viral infection, Immunologia aplicada; Marcadors predictius; Infecció viral, Inmunología aplicada; Marcadores predictivos; Infección viral, Quantitative or qualitative differences in immunity may drive clinical severity in COVID-19. Although longitudinal studies to record the course of immunological changes are ample, they do not necessarily predict clinical progression at the time of hospital admission. Here we show, by a machine learning approach using serum pro-inflammatory, anti-inflammatory and anti-viral cytokine and anti-SARS-CoV-2 antibody measurements as input data, that COVID-19 patients cluster into three distinct immune phenotype groups. These immune-types, determined by unsupervised hierarchical clustering that is agnostic to severity, predict clinical course. The identified immune-types do not associate with disease duration at hospital admittance, but rather reflect variations in the nature and kinetics of individual patient’s immune response. Thus, our work provides an immune-type based scheme to stratify COVID-19 patients at hospital admittance into high and low risk clinical categories with distinct cytokine and antibody profiles that may guide personalized therapy., This work was supported by Health Holland LSHM20056 grant (PDK), in part from the European Union’s Horizon 2020 research and innovation program under grant agreement No 779295 (PDK), in part supported by the Erasmus foundation (BJAR), grant PI20/00416 from the Instituto de Salud Carlos III (RPB) and the European Regional Development Fund (ERDF) (RPB).